GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
A phase 1/2 trial of Pembrolizumab, Lenvatinib in cervical cancer and non-small-cell lung cancer, run by GI Innovation, Inc., now recruiting.
Overview
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04977453 by GI Innovation, Inc., with 317 participants planned, started 2021-08-02 and due to reach its primary completion in 2028-06-30. Interventions recorded: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A. Conditions listed: Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialLEAP-002
Shares Lenvatinib, Pembrolizumab.
- TrialPembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge
Shares Lenvatinib, Pembrolizumab.
- TrialSafety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Shares Lenvatinib, Pembrolizumab, Small-cell lung cancer.
- TrialLITESPARK-012
Shares Lenvatinib, Pembrolizumab.
- TrialPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Shares Lenvatinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Shares Lenvatinib, Pembrolizumab.
- TrialA Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Shares Lenvatinib, Pembrolizumab.
- TrialA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Shares Lenvatinib, Pembrolizumab.